Do Children Taking SGAs Get Metabolic Monitoring?
Careful monitoring of adverse effects of psychotropic drugs in general and second-generation antipsychotics in particular falls below recommended standards for children and adolescents.
A New Treatment for Parkinson Disease Psychosis
In a placebo-controlled study of patients with Parkinson disease and psychosis, the 5-HT-2A receptor inverse agonist pimavanserin improved psychotic symptoms and did not worsen motor signs.
Ramelteon (Rozerem) to Prevent Delirium?
Preliminary results from using the melatonin-receptor agonist ramelteon (Rozerem) in hospitalized patients to prevent delirium are encouraging.
Starting Dose of Eszopiclone Lowered to Avoid Next-Day Impairment; Study Examines Determinants of Antipsychotic Treatment Response
Anxiolytics, Hypnotics, and Mortality Risk
In a retrospective cohort study, a significant association was found between the use of anxiolytic and hypnotic drugs and an increased risk of death.
About the Editorial Advisory Committee
Editorial Advisory Committee:
Ross J. Baldessarini, M.D.
Joseph Biederman, M.D.
Rubin Bressler, M.D.
Andrew W. Brotman, M.D.
Ned Cassem, M.D.
Harold J. DeMonaco, M.S., R.Ph.
Susan R. Donaldson, M.D.
William E. Falk, M.D.
John Greist, M.D.
James W. Jefferson, M.D.
David Katzelnick, M.D.
Samuel J. Keith, M.D.
Martin B. Keller, M.D.
John Racy, M.D.
Eric M. Reiman, M.D.
Jerrold F. Rosenbaum, M.D.
A. John Rush, M.D.
Alan F. Schatzberg, M.D.
Nina R. Schooler, Ph.D.
Michael E. Thase, M.D.
Joanne Doller Wojcik, R.N., M.S.
Alan J. Gelenberg, M.D.
Heather S. Hopkins